In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $48.46 in the prior trading day, Novo Nordisk ADR (NYSE: NVO) closed at $46.51, down -4.02%. In other words, the price has decreased by -$4.02 from its previous closing price. On the day, 43.12 million shares were traded. NVO stock price reached its highest trading level at $49.56 during the session, while it also had its lowest trading level at $46.285.
Ratios:
Our goal is to gain a better understanding of NVO by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.65. For the most recent quarter (mrq), Quick Ratio is recorded 0.57 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.52.
Morgan Stanley Downgraded its Equal-Weight to Underweight on September 29, 2025, while the target price for the stock was maintained at $47.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 205775798272 and an Enterprise Value of 275297239040. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.55, and their Forward P/E ratio for the next fiscal year is 12.17. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.57. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.35 while its Price-to-Book (P/B) ratio in mrq is 7.73. Its current Enterprise Value per Revenue stands at 0.872 whereas that against EBITDA is 1.715.
Stock Price History:
The Beta on a monthly basis for NVO is 0.67, which has changed by -0.54794776 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $112.52, while it has fallen to a 52-week low of $45.05. The 50-Day Moving Average of the stock is -16.23%, while the 200-Day Moving Average is calculated to be -30.07%.
Shares Statistics:
The stock has traded on average 15.51M shares per day over the past 3-months and 16863590 shares per day over the last 10 days, according to various share statistics. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.01% of the company’s shares, while institutions hold 8.62% stake in the company. Shares short for NVO as of 1760486400 were 26671758 with a Short Ratio of 1.72, compared to 1757894400 on 28735135. Therefore, it implies a Short% of Shares Outstanding of 26671758 and a Short% of Float of 0.7900001.
Dividends & Splits
In the trailing 12 months, NVO’s forward annual dividend rate was 11.65, compared to 1.73 this year. Against a Trailing Annual Dividend Yield of 0.24040446. The stock’s 5-year Average Dividend Yield is 1.55. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-03-31 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
Its stock is currently analyzed by 1.0 different market analysts.
Analysts are recommending an EPS of between $22.99 and $22.74 for the fiscal current year, implying an average EPS of $22.86. EPS for the following year is $24.29, with 4.0 analysts recommending between $24.77 and $24.04.
Revenue Estimates
3 analysts predict $78.68B in revenue for. The current quarter. It ranges from a high estimate of $79.92B to a low estimate of $77.48B. As of. The current estimate, Novo Nordisk ADR’s year-ago sales were $85.68BFor the next quarter, 3 analysts are estimating revenue of $76.16B. There is a high estimate of $76.16B for the next quarter, whereas the lowest estimate is $76.16B.
A total of 11 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $313.25B, while the lowest revenue estimate was $305.86B, resulting in an average revenue estimate of $308.88B. In the same quarter a year ago, actual revenue was $290.4BBased on 19 analysts’ estimates, the company’s revenue will be $325.12B in the next fiscal year. The high estimate is $351.1B and the low estimate is $297.43B.
